Study of 18F-JSS20-183A for Tauopathies
This study is testing a new imaging agent called 18F-JSS20-183A. Researchers want to see how this agent moves through your body, how it's processed, and how much of it reaches your brain. The goal is to use 18F-JSS20-183A with a PET scan (a type of imaging) to find a specific protein called 4Rtau, which builds up in the brains of people with conditions like Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and certain types of Frontotemporal Lobar Degeneration (FTLD). People with Parkinson's disease, Alzheimer's disease, and healthy volunteers between 40 and 85 years old can join this study.
- Study design
- This is an interventional study planning to enroll up to 90 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would have a 2-hour PET scan with 18F-JSS20-183A, a brain MRI, another PET scan (Amyloid PET), and neurological assessments including a video interview.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will measure how the imaging agent moves through your body and how much reaches your brain for up to 4 weeks after the PET scan.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A
At a glance
Conditions
Where it's being run
2 sites across 2 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Organ Biodistribution or Dosimetry4 weeks
Determine biodistribution of the radioactive investigational drug, 18F-JSS20-183A and calculate human dosimetry. A second IV or an arterial line may be placed in the arm contralateral to the side of injection for blood metabolite analysis and/or radioactive counts at various times during the scanning session. Biodistribution, metabolism, excretion and pilot brain uptake data will be collected and human dosimetry will be calculated.
- PET Uptake of Tracer4 weeks
Determine whether there is selective uptake of 18F-JSS20-183A in people with taupathies compared to healthy volunteers and non-tau depositing neurodegenerative disease.